Full-Time

Gastroenterology Health & Science Sales Specialist

Boston, MA

Posted on 10/14/2025

Pfizer

Pfizer

10,001+ employees

Biopharmaceutical company develops medicines and vaccines

Compensation Overview

$101.5k - $245.4k/yr

+ Quarterly Sales Incentive Bonus

No H1B Sponsorship

Boston, MA, USA

Remote

Must live within 50 miles of the territory (Boston area). Some travel to accounts/office locations within the territory; overnight stays may be required depending on territory size.

Category
Sales & Account Management (1)
Required Skills
Sales
Data Analysis
Requirements
  • Bachelor’s Degree OR an associate’s degree with 6+ years of experience; OR high school diploma (or equivalent) with 8+ years of relevant experience.
  • Minimum of 3 years of previous Pharmaceutical biotech or medical marketing/promotional/sales experience, a promoted position and or developmental role with demonstrated leadership across peer groups with experienced marketing, promotional and sales in a specialized market where third-party reimbursement and service center has been utilized.
  • Have a history of marketing, promotional or sales success, strong territory management skills, outstanding communications skills, as well as demonstrated teamwork, leadership ability and accountability.
  • Must live within 50 miles of the territory.
  • Valid US driver’s license and a driving record in compliance with company standards.
Responsibilities
  • Ability to effectively identify and implement the most efficient virtual/in-person engagement strategies, by customer, to maximize overall effectiveness and impact. Develops and implements effective business and territory call plans and adapts based on self-identified opportunities and insights.
  • Effectively builds rapport and relationships with customers across virtual and F2F environments; maintains a methodical approach toward call objectives (e.g., clear next steps and appropriate documentation, managing to KPIs); utilizes current digital tools effectively (e.g., Veeva Engage, Zoom, Microsoft Office) as well as adapts quickly to new/beta tools (e.g., digital triage app) for successful customer engagement; leverages analytics to assist with developing insights and next best action plans.
  • Compliantly delivers relevant, targeted messaging utilizing approved materials via customer engagement to drive product demand (ask the HCP to change their prescribing behavior/close sales) and leverages account priorities to drive a positive business outcome; proactively provides insights for the development of new and innovative approved product messaging and resources.
  • Leverages product and disease state knowledge to appropriately educate providers on unbranded and branded product value proposition for relevant patient populations and effectively utilizes approved clinically oriented disease state information, as applicable).
  • Works effectively with HCPs and directs office staff to plan for customer engagements in multiple formats (e.g., virtual and in-person).
  • Responsible for strategic deployment of approved Pfizer resources to support provider and patient’s needs (e.g., samples, vouchers, co-pay resources and patient education); works effectively across multiple virtual engagement platforms based on customer preferences/compliance guidelines; able to integrate guidance from management and other support functions (Marketing, Strategy) technical solutions (e.g., content recommendation engines) into pre-call planning; proactive planning and optimization of call environment in multiple locations; able to effectively plan day-to-day work based on personal and customer schedules; collaborate effectively with other Customer-Facing (CF) colleagues and Pfizer Connect team members.
  • Appropriately support patients’ access to Pfizer products by providing relevant information to HCPs on Reimbursement, Patient Assistant Program (PAP), Pfizer hub programs, and Co-Pay Resources.
  • Present terms of sale of product or existing contract terms where appropriate and with approved language; proactively answer on-label questions; proactively introduce customers to future state Pfizer on-demand portal (Galaxy) with access to appropriate targeted content.
  • Collaborates effectively and compliantly with cross-functional colleagues, including Field Medical, Reimbursement and Key Account Management, to address customer inquiries and advance Pfizer objectives. Able to use triaging protocols and digital apps to create rapid connections with appropriate SMEs to address customer inquiries.
  • Effectively use calendaring tools, leadership goals, and personal insights to address customer priorities calls effectively; and bring insights from customer surveys to leadership to improve model.
Desired Qualifications
  • 3-5 years specialty marketing/promotional/sales experience
  • Strong knowledge of disease states, therapeutic areas, and products
  • Deep knowledge of applicable customers and markets (prescribers/HCPs/institutions/organizations)
  • Strategic account marketing, promotional, sales and management skills.
  • Superior marketing, promotional, sales, technical and relationship building skills
  • Demonstrated track record of assessing account needs and bringing relevant information and resources to drive performance
  • Demonstrated track record of strong business acumen, problem solving, strategic thinking, data analytical skills and project management skills, as well as excellent planning and prioritization skills
  • Demonstrated ability to engage, influence and support customers throughout the marketing, promotional and sales process, excellent communication, and interpersonal and leadership skills.
  • Demonstrated ability to quickly learn and embrace new ways of working in a rapidly changing environment.
  • Possess the ability to work in a matrix environment and to leverage multiple resources to meet customer needs and deliver results.
  • Demonstrated track record of strong leadership, cross functional leadership, collaboration, and effective utilization of available resources to drive performance.
  • Experience working with key thought leaders or high influence customers in large group practices, hospitals, or managed care organizations preferred.
  • Strong organizational and analytical skills are also required and ability to analyze and draw appropriate conclusions using sales data/call reporting software/applications and able to adapt to Pfizer’s long-range technology adapting and learning to use new technology to deliver in bringing Pfizer information to market
  • Change agile and able to adapt quickly to workplace changes
  • Exceptional time management, and planning and organizing skills

Pfizer is a global biopharmaceutical company that discovers, develops, manufactures, and sells medicines and vaccines for a range of health needs, including vaccines, oncology, and other specialized therapies. Its products work by using biological mechanisms to prevent or treat diseases—vaccines train the immune system to fight infections, while medicines target cancer and other conditions. Pfizer differentiates itself through its large worldwide footprint, broad portfolio across multiple therapeutic areas, and partnerships (notably with BioNTech) that expanded its reach in vaccines and cutting-edge therapies. The company also engages in public health initiatives, such as efforts to provide vaccines to underserved populations. Pfizer’s broad goal is to improve global health by delivering safe and effective medicines and vaccines through research, development, and wide international distribution.

Company Size

10,001+

Company Stage

IPO

Headquarters

New York City, New York

Founded

1849

Simplify Jobs

Simplify's Take

What believers are saying

  • Newer medicines grew 22% operationally in Q1 2026, led by Padcev up 39% and Lorbrena up 32%.
  • VYNDAMAX patent extended to 2031 secures 75% US prescription share in cardiology.
  • ELREXFIO Phase 3 data supports earlier multiple myeloma use against J&J and BMS competitors.

What critics are saying

  • Eliquis patent expiry in 2026 triggers generic entry, eroding $17B peak cardiology sales.
  • Ibrance loses exclusivity in 2027, unleashing generics that destroy $5B breast cancer revenue.
  • Rigel deal forfeits Pfizer's Veppanu royalties, ceding 50-70% of breast cancer peak sales.

What makes Pfizer unique

  • Pfizer pioneered VEPPANU, FDA-approved first PROTAC therapy for ESR1-mutated breast cancer in May 2026.
  • Seagen acquisition doubled Pfizer's ADC trials across bladder, breast, lung, and colorectal cancers.
  • Flatiron Health collaboration since 2014 integrates real-world data for NSCLC and CRC development.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

401(k) Retirement Plan

401(k) Company Match

Paid Vacation

Paid Sick Leave

Paid Holidays

Hybrid Work Options

Relocation Assistance

Company News

Pfizer
May 4th, 2026
Esperion Therapeutics Completes $22.75 M Series A Financing | Pfizer

ANN ARBOR, Mich. & NEW YORK--(BUSINESS WIRE)--ANN ARBOR, Mich

Yahoo Finance
Apr 9th, 2026
Pfizer beats Q4 revenue estimates by 5.5% as branded pharma sector faces mixed earnings

Ten branded pharmaceuticals stocks reported mixed fourth-quarter results, with revenues missing analysts' consensus estimates by 1.7% on average. Share prices have declined 3% on average since the latest earnings results. Pfizer reported revenues of $17.56 billion, down 1.2% year-on-year but exceeding analysts' expectations by 5.5%. The stock has risen 2.8% since reporting and currently trades at $27.40. Eli Lilly delivered the strongest performance amongst peers, reporting revenues of $19.29 billion, up 42.6% year-on-year and beating expectations by 7.4%. Despite the impressive results, shares have fallen 5.2% since reporting to $951.77. The industry faces tailwinds from precision medicine advances and AI adoption, but headwinds include regulatory scrutiny, pricing pressures and patent cliffs for blockbuster drugs.

Yahoo Finance
Apr 7th, 2026
Pfizer stock seen as undervalued buy despite pipeline growth and strategic acquisitions

Pfizer, trading at less than 10 times estimated future earnings, presents significant upside potential despite recent revenue declines. The pharmaceutical company's sales fell from $101 billion in 2022 to under $63 billion last year as COVID-19 product revenues diminished. However, Pfizer has been actively preparing for growth through strategic acquisitions. In 2023, it purchased oncology specialist Seagen for $43 billion, gaining access to promising antibody-drug conjugates for cancer treatment. Last year, it acquired GLP-1 drugmaker Metsera for up to $10 billion to enter the anti-obesity drug market. The company maintains over 100 drug candidates in development. Whilst facing near-term patent cliffs on key drugs, Pfizer's extensive pipeline and low valuation suggest substantial long-term potential for investors willing to accept calculated risk.

Yahoo Finance
Apr 6th, 2026
Pfizer shares climb 7.1% in six months as organic revenue grows 10.1% annually

Pfizer shares have climbed to $28.30, delivering a 7.1% return over the past six months and outperforming the S&P 500 by 9.4 percentage points. The pharmaceutical company's organic revenue has grown at a solid 10.1% year-on-year average over the last two years, whilst its adjusted operating margin rose 17.8 percentage points to reach 35.1% for the trailing 12 months. However, Pfizer's long-term performance shows slower growth, with revenue expanding at just a 5.6% compound annual growth rate over the past five years, underperforming the broader healthcare sector. The stock currently trades at 9.6× forward price-to-earnings ratio. Founded in 1849, Pfizer develops and manufactures medicines and vaccines for various diseases and conditions globally.

Yahoo Finance
Mar 30th, 2026
Pfizer shares up 25% since Jim Cramer said 'pass' on Mad Money

Pfizer shares have risen 25% since Jim Cramer advised investors to "pass" on the stock in April 2025, citing uncertainty over potential tariffs and taxes on pharmaceutical companies. The shares are up 6.7% over the past year and 7.4% year-to-date. A notable gain occurred between 29 September and 1 October, when shares jumped 14% following Pfizer's announcement that it would lower Medicaid drug prices to match those in developing countries as part of the Trump administration's TrumpRx initiative. However, shares fell 3.3% on 3 February after the company reported fourth-quarter results of $17.6 billion in revenue and $0.66 adjusted earnings per share. Pfizer is developing a once-monthly weight loss treatment and currently offers an 8% dividend yield.

INACTIVE